Mycobacterium bovis BCG prime DNA (Mycobacterium tuberculosis genes)-booster vaccinations have been shown to induce greater protection against tuberculosis (TB) than BCG alone. This heterologous prime-boost strategy is perhaps the most realistic vaccination for the future of TB infection control, especially in countries where TB is endemic. Moreover, a prime-boost regimen using biodegradable microspheres seems to be a promising immunization to stimulate a long-lasting immune response. The alanine proline antigen (Apa) is a highly immunogenic glycoprotein secreted by M. tuberculosis. This study investigated the immune protection of Apa DNA vaccine against intratracheal M. tuberculosis challenge in mice on the basis of a heterologous prime-boost regimen. BALB/c mice were subcutaneously primed with BCG and intramuscularly boosted with a single dose of plasmid carrying apa and 6,6=-trehalose dimycolate (TDM) adjuvant, coencapsulated in microspheres (BCG-APA), and were evaluated 30 and 70 days after challenge. This prime-boost strategy (BCG-APA) resulted in a significant reduction in the bacterial load in the lungs, thus leading to better preservation of the lung parenchyma, 70 days postinfection compared to BCG vaccinated mice. The profound effect of this heterologous prime-boost regimen in the experimental model supports its development as a feasible strategy for prevention of TB.
T uberculosis (TB) is still one of the leading causes of death from a single infectious agent, causing 1.6 million deaths each year, mostly in developing countries (1, 2) . Preventive efforts to control the spread of TB in various parts of the world rely on the use of Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine. Over 90% of children are immunized with BCG annually in most developing countries, making it the most widely used human vaccine. This vaccine offers protection against severe manifestations of childhood TB, including meningeal and miliary TB. Moreover, application of the BCG vaccine has considerably reduced the incidence of infant TB in areas where TB is endemic (3, 4, 5) . However, its protective effect decreases with advancing age, and it is insufficient to control pulmonary TB, the most frequent occurrence of the disease, in adults. Heterologous prime-boost vaccines are proposed to enhance specific immunity primed by childhood BCG vaccination (6) and are one of the best candidates for novel TB vaccines. Specifically, DNA-based vaccines could be a good choice for improving BCG efficacy because they can stimulate both humoral and cell-mediated immunity in experimental TB models (7) .
Antigens present in the mycobacterial culture filtrate (CF) are inducers of protective immunity against Mycobacterium tuberculosis challenge in mice (8, 9, 10) , guinea pigs (11, 12) , and nonhuman primates (13) . Alanine proline antigen (Apa) is a major immunodominant antigen secreted by the M. tuberculosis complex (14, 15) . This glycoprotein is a fibronectin attachment protein (FAP) and can mediate mycobacterial binding to host cells as a potential adhesin (16) . Apa was selected based on its ability to be recognized by lymphocytes and by antibodies raised in guinea pigs immunized with living mycobacteria (17) . This antigen has been previously shown to be highly antigenic in humans, in vitro (18, 19) . Additionally, an Apa-encoding DNA vaccine (Apa DNA) induces strong Th1 and Th2 responses and is capable of activating significant protective responses in mice (20) and guinea pigs (18) .
To further improve the effectiveness of subunit vaccines, adjuvants can be introduced in the vaccine formulation. 6,6=-Trehalose dimycolate (TDM) is present in M. tuberculosis cell walls and acts as a potent immunomodulator, preferentially inducing Th1 responses, thus making it an interesting adjuvant for TB vaccines (21) . Combined with delivery systems such as microspheres, antigens (DNA, proteins, or peptides) can be encapsulated and protected from harsh conditions. The microparticles can be coencapsulated with or without immune stimulants and can be administered by different routes. Moreover, microspheres do not induce the toxicity that is generally associated with adjuvants (22, 23, 24) . The choice of an appropriate adjuvant formulation and delivery system is crucial in obtaining optimal vaccine stability and effectiveness (25) .
In this study, we investigated the immune protection against intratracheal M. tuberculosis challenge by priming with BCG and boosting with a single dose of Apa DNA vaccine, containing TDM Briefly, 10 mg of microspheres was dissolved in 1 ml of acetonitrile. After centrifugation, the precipitated plasmid was pelleted down and supernatant containing polymer was discarded. The pellet was redispersed in phosphate-buffered saline (PBS) (50 mM, pH 7.4) and the samples (in triplicate) were centrifuged again. The supernatant was preserved and the residue was further dissolved in 0.1 N NaOH. The plasmid in aqueous and alkaline extractions was estimated using a NanoDrop ND-1000 (Thermo).
Culture filtrate antigens. The CF was kindly donated by Gilles Marchal of Institut Pasteur, Paris, France. It was prepared using an M. tuberculosis H37Rv 15-day culture, as previously described (15) .
Immunization and M. tuberculosis infection. BALB/c mice were separated into 5 experimental groups: (i) PBS (received saline, nonvaccinated and noninfected), (ii) BCG (received 1 dose of BCG), (iii) BCG-PVAX (received prime BCG-boost pVAX-TDM-Me), (iv) BCG-APA (received prime BCG-boost pVAXapa-TDM-Me), and (v) TB (nonvaccinated and infected with M. tuberculosis H37Rv). Immunizations were performed according to a heterologous schedule (see below). The PBS group received 50 l of saline in each quadriceps subcutaneously (s.c.) and intramuscularly (i.m.) in 2 doses, and mice were not infected. The BCG group received a single vaccination with 5 ϫ 10 5 BCG Moreau bacilli and 1 dose of saline, which were administered s.c. For heterologous prime-boost vaccination schedules, mice were primed with 5 ϫ 10 5 BCG Moreau bacilli s.c. and boosted i.m. after 30 days with 100 g of pVAX-TDM-Me (BCG-PVAX) or pVAXapa-TDM-Me (BCG-APA) formulation. For the TB control group, mice were injected with 50 l of saline in each quadriceps s.c. and in 2 doses i.m. Thirty days after the last immunization, mice were anesthetized with 2,2,2-tribromoethanol (Acros) by intraperitoneal administration. The trachea was exposed and inoculated with 1 ϫ 10 5 viable bacilli of the M. tuberculosis H37Rv strain (ATCC 27294). The incision was sutured with sterile silk. Thirty and 70 days after infection (corresponding to the initial and chronic phases of infection, respectively), mice were euthanized for evaluation of the protective immune response. The microsphere formulations consisted of 30 g of plasmidial DNA (pVAXapa or pVAX) in TDM-loaded PLGA 50:50 microspheres. All procedures were performed in a BSL3 room facility in the University of São Paulo at the Ribeirão Preto School of Medicine.
CFU determination. The right lower and middle lobes of lungs were digested using Liberase Blendzyme 2 (Roche, Indianapolis, IN) diluted (0 to 5 g/ml) in incomplete RPMI 1640 medium (Sigma). Spleens were placed in a petri dish containing incomplete RPMI 1640 medium and then fragmented with the aid of anatomical sterile forceps. Serial dilutions of the digested lungs and macerated spleens were plated on 7H11 Middlebroock agar medium (Difco Laboratories, Detroit, MI) and used for the CFU assay as previously described (25, 26) . Colonies were counted after 28 days of incubation at 37°C.
Histopathological analysis. The right upper lobes of the lungs were fixed in 10% formalin, embedded in paraffin blocks, prepared routinely, and then sectioned for evaluation by light microscopy. For the histopathological analyses, 5-m-thick sections were stained with hematoxylin and eosin.
The slides from each of the mouse groups were examined in a blind study by a pathologist, to establish the pattern and extent of the histological changes. A grade was established on the basis of the most severely inflamed section on each slide. After the slides were surveyed to identify the maximal response for each category, which was designated 4ϩ (intense/severe), additional slides representing intermediate/moderate, low, and very low responses were designated 3ϩ, 2ϩ, and 1ϩ, respectively. The absence of response was designated by a minus sign ( Table 1 ). The results shown in Table 1 are for one representative out of 3 independent experiments.
Statistical analysis. Assessment of the experiments and statistical analysis were performed by using analysis of variance (ANOVA) and the Tukey test to determine the difference between the experiment group and the control groups. The data are expressed as means Ϯ standard devia-tions (SDs), and P values of Ͻ0.05 were considered statistically significant. Analysis was performed using the SPSS 16.0 statistical software package (IBM Company, Chicago, IL).
RESULTS

Plasmid construction and expression of Apa antigen.
Apa DNA lacking the signal sequence was cloned by PCR from pAG831 (20) . The amplified fragment was subcloned into pGEM-T Easy and further cloned into pVAX1 using EcoRI and XhoI sites and transformed into competent E. coli DH5␣ cells. The recombinant plasmid was identified by enzyme digestion on an agarose gel stained with ethidium bromide. Figure 1A shows the 900-bp fragment that corresponds to apa and the 3,054-bp fragment that corresponds to the pVAX plasmid (Fig. 1A, lane 3) and pVAX digested by XhoI (Fig. 1A, lane 2) .
BHK-21 cells were transfected with pVAX-apa. Total protein extract was obtained from transfected cells, and the presence of Apa in the extract was confirmed by Western blotting using an Apa-specific polyclonal antibody (Fig. 1B) . The expression of Apa was confirmed by the presence of a band of 47 kDa, the expected size of the Apa protein (Fig. 1B, lane 3) . Total protein extracts from BHK-21 cells transfected with plasmid pVAX (Fig. 1B , lane 2) and from untransfected controls (Fig. 1B , lane 1) did not express Apa protein, as expected.
The heterologous prime (BCG)-boost (pVAXapa-TDM-Me) regimen protects mice against M. tuberculosis infection. To improve BCG protection and evaluate a heterologous immunization schedule ( Fig. 2A) using the pVAXapa-TDM-Me vaccine, mice were challenged with M. tuberculosis. At 30 (Fig. 2B) and 70 (Fig.  2C ) days after infection, which correspond to the initial and chronic phases of infection, respectively, the BCG and primeboost groups showed significant reduction in the bacterial loads in lungs compared with the TB group (30 days, P Ͻ 0.05; 70 days, P Ͻ 0.001).
Most importantly, 70 days postinfection, the strongest protective effect was seen in BCG-APA-vaccinated mice, with a significant inhibition of the growth of M. tuberculosis in the lungs compared with that in mice vaccinated with BCG alone (P Ͻ 0.005) or with BCG-pVAX (P Ͻ 0.05) (Fig. 2C) . The BCG-APA group (4.6 logs) exhibited a reduction in the bacterial load which was nearly 1 order of magnitude lower than that of the BCG (5.4 logs) and BCG-PVAX (5.3 logs) groups, as well as an important reduction of approximately 2.0 logs compared with the TB group (6.6 logs).
Evaluation of the extrapulmonary protective immune response indicated that either heterologous immunization or BGC alone was effective in controlling the bacterial growth in the spleen. In both the early (Fig. 2D ) and chronic ( Fig. 2E ) phases of experimental infection, all groups of immunized animals (BCG, BCG-PVAX, and BCG-APA) exhibited a reduction in bacterial growth of about 1 log compared to the TB infection control group (P Ͻ 0.005).
Histological evaluation of the lung specimens from the PBS control mice showed no pathological changes, with well-preserved lung parenchyma, clearly defined alveolar spaces, and no inflammatory cells in the tissue and normal lumen ( Fig. 3A and  B) . In contrast, evaluation of the lung specimens from nonimmunized and infected mice (TB group) showed moderate impairment of the lung parenchyma and moderate inflammation with numerous granulomas 30 days after infection ( Fig. 3C and Table  1 ). These granulomas were formed by many foam cells in their central regions. In addition, intense interstitial chronic inflammatory infiltrates were observed mostly in the peribronchiolar regions. This inflammatory infiltrate was accompanied by diffuse thickening of the alveolar walls and reductions in air space. By the later stage of infection, i.e., at 70 days, severe lung injury was diagnosed on the basis of the presence of intense inflammatory infiltrates, represented by multiple granulomas with many foam a Mice (n ϭ 5) were vaccinated with BCG, BCG-pVAX-TDM-Me, or BCG-pVAXapa-TDM-Me, as described in the legend to Fig. 3 . Thirty days after the last immunization, we performed an intratracheal challenge with M. tuberculosis, and at 30 and 70 days after infection, the lungs were collected and processed for histopathological analysis. The symbols indicate the absence (Ϫ) or the very low (ϩ), low (ϩϩ), moderate (ϩϩϩ), or intense (ϩϩϩϩ) presence of each parameter evaluated. There were rare (ϩ), some (ϩϩ), many (ϩϩϩ), or numerous (ϩϩϩϩ) giant cells and foam cells. The results of one representative experiment out of three independent experiments are shown.
cells and some cholesterol clefts ( Fig. 3D and Table 1 ). However, the interstitial inflammatory infiltrate was less intense than that observed 30 days postinfection in the same group. The injury of lung tissue in mice immunized with BCG alone (Fig. 3E and F) and the BCG-PVAX group (Fig. 3G and H) was more severe than that seen in the BCG-APA group (Fig. 3I and J) , in agreement with the bacterial loads measured at 30 and 70 days postinfection. In both groups (BCG and BCG-PVAX), the presence of peribronchial lymphocytes and few granulomas was observed at 30 days postinfection, with the notable formation of lymphoid aggregates and an increased number of granulomas at 70 days postinfection. However, the lung parenchyma of the BCG-PVAX group had more preserved areas, as well as lower inflammation than BCG-immunized mice. In the group administered BCG alone, giant and foam cells were rarely observed during early infection; however, some foam and giant cells were found in the later stage of infection. Moreover, in the BCG-PVAX group, at 30 days postinfection, few foam cells were found but fewer giant and foam cells were noted at 70 days postinfection compared to the BCG group. When animals were immunized with the Apa DNA formulation in the heterologous immunization regimen (BCG-APA), better preservation of lung parenchyma was observed than that in the other immunized groups following M. tuberculosis infection. In the lung tissue of this group, few granulomas were observed, foam cells were rare (Fig. 3J) , and giant cells were absent. Furthermore, the majority of specimens from these immunized mice exhibited few lymphocytic inflammatory infiltrates in the alveolar walls at 30 and at 70 days after infection (Fig. 3I and J and Table 1 ) mainly adjacent to the rare granulomas observed at 70 days postinfection (Fig. 3J) . These findings indicate that mice treated using the BCG-APA strategy showed best preservation of lung parenchyma among all the immunized groups, and especially compared to the TB group, in the chronic phase of infection; the results of the BCG-APA group were similar to those of the PBS group. In addition, these findings corroborate the significant reduction in the number of bacteria detected in the lung tissue of these animals. Images of the lung lobes of the different groups presented in Fig. 4 show a similar pattern and are consistent with the above-mentioned data.
DISCUSSION
In this study, we showed that heterologous prime-boost vaccination with prime BCG administered s.c. followed by pVAXapa-TDM-Me boost immunization (BCG-APA) administered i.m. provided significantly greater protection than that conferred by a single s.c. dose of BCG in controlling bacterial loads, leading to better preservation of the lung parenchyma, after 70 days of infection.
Many studies have shown that using BCG as a prime combined with a novel boost vaccine is more efficacious than BCG alone (31) . However, it is also known that revaccination with BCG in humans does not confer additional protection and, in some cases, may be deleterious to protection against TB (32, 33) . Therefore, the development of a new vaccine capable of promoting immunity in individuals who have already received the BCG vaccine would be very beneficial (6) .
As reported previously, the order of prime-boost vaccination may not be critical for enhancing protection against experimental TB (34) . Priming but not boosting with a DNA vaccine could also increase the survival time of BCG-vaccinated mice against challenge with M. tuberculosis (35, 36) . This vaccination strategy is often assessed by CFU counting and pathology score, but longterm survival is not always evaluated. Therefore, there is still no consensus in the order of prime-boost vaccination, and the improvement of the BCG vaccine merits further investigation.
Previous studies have shown that plasmids with apa-induced humoral and cell-mediated immunity provided significant protection against TB in mice and guinea pigs (18, 20) . Subsequently, immunization with 3 doses of apa was shown to be highly immunogenic in a murine model (36) . Recently, among the nine M. tuberculosis recombinant proteins evaluated, the Apa antigen was found to be highly antigenic following BCG vaccination (37) . Our data on heterologous prime-boost immunization also confirmed this immunogenicity induced by Apa, after an intratracheal M. tuberculosis infection, and showed that this immunization lasts longer than the one conferred by BCG vaccination alone.
The importance of the preservation of lung morphology along with bacterial clearance has been described previously (38, 39) . Although some TB vaccines show highly prospective clearance of the bacillus, they may induce an exacerbated inflammatory response that culminates with lung necrosis (39) . On the other hand, it was also reported that some other vaccines do not cause this damage but are ineffective in reducing the bacterial load to levels comparable with that induced by BCG (40) . In addition, our group showed that consistent cellular and humoral responses generated by vaccination do not prevent the development of pulmonary injury in immunized mice (27) . In contrast to those results, our results in this study showed that the most significant reduction in bacterial load of the lungs was associated with an important reduction of tissue injury in mice vaccinated using the BCG-APA strategy, 30 and 70 days after infection, compared with controls and BCG-vaccinated mice alone.
The advantageous properties of the microsphere-based delivery system likely account for the superior protection obtained in this study compared to that seen in previous studies.
Most importantly, significant protection was accomplished by a boosting immunization with only one dose of pVAXapa-TDM-Me. Indeed, delivery systems such as antigen-encapsulated microspheres enhance the binding, uptake, and half-life of antigens (41) , leading to a reduction in the number of doses in the immunization schedule (23) . The slow degradation of such a delivery system allows sustained delivery of the antigen. All these data could explain the high level of protection conferred by this formulation compared to the other formulations that used only naked apa DNA (18, 34) . Moreover, biodegradable PLGA microspheres have a proven safety record and an established utility in marketed products for controlled delivery of several peptide drugs (42) . In this context, the combination of microspheres and the TDM adjuvant, which has been described as a potent immunomodulator (22) , is an interesting and potentially beneficial approach to improve vaccine formulations and provide long-lasting protection against TB (23, 43) . However, the mechanism of enhanced protection conferred by pVAXapa-TDM-Me, as well as the mechanism of protection conferred by BCG itself, remains to be determined.
In conclusion, the improved protection conferred by the combination of BCG priming followed by a pVAXapa-TDM-Me boosting immunization (BCG-APA) provides evidence for the hypothesis that the efficacy of BCG vaccination can be improved by subsequent boosting with a DNA vaccine. Further investigation on this topic is warranted. 
